Jason Wittes
Stock Analyst at Roth Capital
(2.60)
# 2,108
Out of 5,246 analysts
58
Total ratings
48.08%
Success rate
3.44%
Average return
Main Sectors:
Stocks Rated by Jason Wittes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Initiates: Buy | $40 | $7.94 | +403.78% | 1 | Sep 4, 2025 | |
| SYK Stryker | Maintains: Buy | $405 → $456 | $316.48 | +44.08% | 11 | May 2, 2025 | |
| FBIO Fortress Biotech | Reiterates: Buy | $15 → $16 | $2.74 | +483.94% | 3 | Mar 11, 2025 | |
| OFIX Orthofix Medical | Reiterates: Buy | $22 | $10.75 | +104.65% | 5 | Feb 26, 2025 | |
| IRMD IRADIMED CORPORATION | Reiterates: Buy | $60 → $72 | $92.10 | -21.82% | 3 | Feb 14, 2025 | |
| TLSI TriSalus Life Sciences | Reiterates: Buy | $11 | $3.26 | +237.42% | 2 | Jan 24, 2025 | |
| GMED Globus Medical | Maintains: Buy | $100 → $115 | $84.81 | +35.60% | 4 | Dec 17, 2024 | |
| DERM Journey Medical | Reinstates: Buy | $11 | $5.96 | +84.56% | 1 | Jun 28, 2024 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $10 | $1.32 | +657.58% | 1 | Jun 26, 2024 | |
| LMAT LeMaitre Vascular | Reinstates: Buy | $100 | $97.75 | +2.30% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.92 | +160.42% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.3069 | +2,832.55% | 2 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $24.19 | +210.05% | 2 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $8.27 | +166.02% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $120 | $85.50 | +40.35% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $206 | $178.81 | +15.21% | 1 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $145 | $203.51 | -28.75% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7.5 | $15.10 | -50.33% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $17.96 | +1,013.59% | 3 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $38.87 | -33.11% | 1 | Feb 22, 2017 |
ARS Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $7.94
Upside: +403.78%
Stryker
May 2, 2025
Maintains: Buy
Price Target: $405 → $456
Current: $316.48
Upside: +44.08%
Fortress Biotech
Mar 11, 2025
Reiterates: Buy
Price Target: $15 → $16
Current: $2.74
Upside: +483.94%
Orthofix Medical
Feb 26, 2025
Reiterates: Buy
Price Target: $22
Current: $10.75
Upside: +104.65%
IRADIMED CORPORATION
Feb 14, 2025
Reiterates: Buy
Price Target: $60 → $72
Current: $92.10
Upside: -21.82%
TriSalus Life Sciences
Jan 24, 2025
Reiterates: Buy
Price Target: $11
Current: $3.26
Upside: +237.42%
Globus Medical
Dec 17, 2024
Maintains: Buy
Price Target: $100 → $115
Current: $84.81
Upside: +35.60%
Journey Medical
Jun 28, 2024
Reinstates: Buy
Price Target: $11
Current: $5.96
Upside: +84.56%
Cardiol Therapeutics
Jun 26, 2024
Initiates: Buy
Price Target: $10
Current: $1.32
Upside: +657.58%
LeMaitre Vascular
May 31, 2024
Reinstates: Buy
Price Target: $100
Current: $97.75
Upside: +2.30%
Mar 5, 2024
Reiterates: Buy
Price Target: $5
Current: $1.92
Upside: +160.42%
Feb 13, 2024
Initiates: Buy
Price Target: $9
Current: $0.3069
Upside: +2,832.55%
Oct 20, 2023
Initiates: Buy
Price Target: $75
Current: $24.19
Upside: +210.05%
Oct 20, 2023
Initiates: Buy
Price Target: $22
Current: $8.27
Upside: +166.02%
Oct 20, 2023
Initiates: Neutral
Price Target: $120
Current: $85.50
Upside: +40.35%
Sep 14, 2022
Initiates: Buy
Price Target: $206
Current: $178.81
Upside: +15.21%
Jun 27, 2022
Reinstates: Buy
Price Target: $145
Current: $203.51
Upside: -28.75%
Mar 3, 2022
Initiates: Buy
Price Target: $7.5
Current: $15.10
Upside: -50.33%
Feb 8, 2022
Initiates: Buy
Price Target: $200
Current: $17.96
Upside: +1,013.59%
Feb 22, 2017
Initiates: Buy
Price Target: $26
Current: $38.87
Upside: -33.11%